F-18-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors

Filizoglu N., Ozguven S., Erdil T. Y.

CLINICAL NUCLEAR MEDICINE, cilt.47, sa.9, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Editöre Mektup
  • Cilt numarası: 47 Sayı: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/rlu.0000000000004177
  • Dergi Adı: CLINICAL NUCLEAR MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: breast cancer, CDK4/6 inhibitor, FDG PET/CT, RIBOCICLIB
  • Marmara Üniversitesi Adresli: Evet

Özet

Dysregulation of the cyclin D-CDK4/6-INK4-RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Despite promising clinical results, the metabolic response to treatment with these new drugs has not been elaborately demonstrated yet. Herein, we presented a patient with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who demonstrated a complete metabolic response on F-18-FDG PET/CT to treatment with a CDK4/6 inhibitor (ribociclib).